Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Acro Biomedical (ACBM) FCF Margin (2017 - 2022)

Acro Biomedical has reported FCF Margin over the past 6 years, most recently at 2.94% for Q4 2022.

  • Quarterly results put FCF Margin at 2.94% for Q4 2022, up 718.0% from a year ago — trailing twelve months through Sep 2023 was 3.72% (up 1830.0% YoY), and the annual figure for FY2022 was 22.4%, down 4739.0%.
  • FCF Margin for Q4 2022 was 2.94% at Acro Biomedical, down from 87.82% in the prior quarter.
  • Over the last five years, FCF Margin for ACBM hit a ceiling of 11457.26% in Q3 2019 and a floor of 23.3% in Q2 2018.
  • Median FCF Margin over the past 5 years was 6.35% (2018), compared with a mean of 969.56%.
  • Biggest five-year swings in FCF Margin: soared 1145744bps in 2019 and later tumbled -464bps in 2021.
  • Acro Biomedical's FCF Margin stood at 12.88% in 2018, then soared by 40bps to 18.05% in 2019, then tumbled by -121bps to 3.78% in 2020, then crashed by -168bps to 10.12% in 2021, then soared by 71bps to 2.94% in 2022.
  • The last three reported values for FCF Margin were 2.94% (Q4 2022), 87.82% (Q1 2022), and 10.12% (Q4 2021) per Business Quant data.